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Abstract
Background: Pluripotent mouse embryonic stem (ES) cells can be induced in vitro to become
neural progenitors. Upon transplantation, neural progenitors migrate toward areas of damage and
inflammation in the CNS. We tested whether undifferentiated and neuralized mouse ES cells
migrate toward media conditioned by glioma cell lines (C6, U87 & N1321) or Stem Cell Factor
(SCF).
Results: Cell migration assays revealed selective migration by neuralized ES cells to conditioned
media as well as to synthetic SCF. Migration of undifferentiated ES cells was extensive, but not
significantly different from that of controls (Unconditioned Medium). RT-PCR analysis revealed that
all the three tumor cell lines tested synthesized SCF and that both undifferentiated and neuralized
ES cells expressed c-kit, the receptor for SCF.
Conclusion: Our results demonstrate that undifferentiated ES cells are highly mobile and that
neural progenitors derived from ES cells are selectively attracted toward factors produced by
gliomas. Given that the glioma cell lines synthesize SCF, SCF may be one of several factors that
contribute to the selective migration observed.
Background
Embryonic stem (ES) cells possess the capacity for unlim-
ited self renewal and can be induced in vitro to become
neural precursors with the potential for therapeutic treat-
ment of nervous system disorders [1-5]. Neural stem cells
(NSCs) are mobile [6], are attracted to regions of brain
injury and can migrate great distances to reach a site of
neural damage [7-10]. In addition, through unknown
mechanisms, they exhibit tropism to brain tumors,
including glioma cells that have left the main tumor mass
and have infiltrated adjacent brain parenchyma
[6,8,11,12]. In vitro migration assays confirm the ability of
isolated NSCs, including those derived from mouse
embryonic stem cells [13], to migrate toward factors pro-
duced by glioma cells [8,14].
Recent studies suggest that stem cell factor (SCF) and stro-
mal cell-derived factor 1α (SDF1α) act as chemoattract-
ants, capable of inducing neural stem cell migration into
regions of brain injury/inflammation. For example, Sun et
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Undifferentiated ES cells exhibit extreme mobility and neuralized ES cells exhibit selective migration toward Glioma Cells and  Conditioned Medium Figure 1
Undifferentiated ES cells exhibit extreme mobility and neuralized ES cells exhibit selective migration toward Glioma Cells and 
Conditioned Medium. A-C, Cell counts were made after a 4 hours incubation with either Unconditioned Medium (UM; DMEM 
and FBS alone), Conditioned Medium or Glioma Cells in the bottom well, for all three glioma cell lines, C6, N1321, and U87 
(as indicated). On Day 0 (undifferentiated ES cells) and on Day 4, large numbers of stem cells migrated toward the bottom well 
with no significant differences in cell counts, regardless of the content of the lower well (Ai-Ci). However, neuralized ES cells 
obtained at Day 8 of the induction protocol exhibited selective migration when Conditioned Medium or Glioma cells were 
placed in the bottom well for all three glioma cell lines, C6, N1321, and U87, respectively (Aii-Cii). At Day 8, significance was 
established at p < 0.05 (*) or p < 0.01 (**) using One-Way ANOVA and a post hoc Dunnet Test.Cancer Cell International 2006, 6:1 http://www.cancerci.com/content/6/1/1
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al. [15] report that in normal mouse brains, endogenous
NSCs are attracted to regions where recombinant SCF has
been introduced, SCF elicits selective migration of neural
stem/progenitor cells in vitro, and after a freezing brain
injury SCF is up-regulated in neurons at the site of injury.
Also, Imitola et al. [16] found in a mouse stroke model
that SDF1α synthesis by astrocytes and endothelial cells is
increased at the site of injury and that exogenous human
NSCs migrate to sites of injury from as far as the contral-
ateral hemisphere to intermingle with SDF1α-expressing
cells. These studies suggest that cytokines, such as SCF and
SDF1α may be involved in attracting stem cells to regions
of injury and inflammation [17].
Since brain tumors can also attract stem cells, perhaps
their mechanism of attraction is similar to that of injury
and inflammation. Support for this comes from reports of
the expression of SCF by certain glioma cell lines [18,19]
and expression of c-kit, the tyrosine kinase receptor for
SCF ligand, by neural stem/progenitor cells [15,20].
Clearly, it is important to characterize the reactions of
stem cells to gliomas, including whether they display the
capacity for selective attraction to tumor cells. In the
present study, we performed in vitro migration assays to
compare the behavior of undifferentiated and neuralized
mouse ES cells toward the human glioma lines U87 and
N1321, rat glioma line C6 and SCF. In addition, we tested
for expression of SCF by the tumor lines and of c-kit by the
ES cells.
Results
Neuralized ES cells selectively migrate to factor(s) 
produced by glioma cell lines
We used in vitro migration assays to test whether undiffer-
entiated or neuralized ES cells displayed selective migra-
tion toward factors produced by rat glioma cell line C6 or
human glioma cell lines U87 and N1231. The migration
experiments consisted of placing either undifferentiated
or neuralized ES cells (at Day 4 or Day 8 of neural induc-
tion) in the top well and a selected tumor cell line or
media conditioned by a tumor cell line in the bottom
well. If the glioma cell lines produced attractants, then
they should cause significantly more stem cells to migrate
from the top well, through the porous membrane toward
the bottom well when compared to Unconditioned
Medium.
Large numbers of undifferentiated ES cells (Day 0 of
induction) migrated toward the bottom chambers with
no significant differences observed in response to the con-
tents of the bottom well (Fig. 1Ai,Bi,Ci). By Day 4 of neu-
ral induction, there also were no significant differences in
cell counts among the three experimental conditions (Fig.
1). Note that for all experimental conditions, migration
on Day 4 of neural induction was significantly (p < 0.01)
lower than on Day 0 (i.e., comparisons were made for cell
counts in response to Unconditioned Medium and for
combined cell counts of Conditioned Medium and Gli-
oma Cells). These results suggested a decreased mobility
of the ES cells as they began to differentiate.
Migration on Day 8 of neural induction indicated a con-
tinued and significant decrease in mobility, when com-
pared to Day 0 or Day 4 of induction (Fig. 1). Importantly
however, the neuralized ES cells on Day 8 of induction
showed selective migration; that is, significantly more
cells migrated toward Conditioned Medium and Tumor
Cells for all three glioma cell lines, when compared to
Unconditioned Medium (Fig. 1Aii,Bii,Cii). These results
suggested that all three glioma cell lines secrete a factor(s)
that acts on the neuralized ES cells as an attractant.
Selective migration of neualized ES cells to SCF
One factor that is upregulated in regions of CNS injury
and inflammation and attracts migratory neural stem cells
is Stem Cell Factor or SCF [15]. Cells isolated on Day 8 of
neural induction were highly attracted to SCF (Fig. 2). The
numbers of cells that migrated through the membrane to
SCF did so in an apparent dose-dependent manner. At
concentrations of 50 ng/ml or higher their migration was
significantly (p < 0.001) greater than for Unconditioned
Medium. No significant differences in numbers of cells
were observed in response to recombinant SCF when the
migration experiments were performed on Day 0 and Day
4 of induction (data not shown).
Stem Cell Factor (SCF) elicited a concentration-dependent  migration of neuralized ES cells (Day 8) Figure 2
Stem Cell Factor (SCF) elicited a concentration-dependent 
migration of neuralized ES cells (Day 8). At concentrations 
above 50 ng/ml of recombinant SCF, significantly more cells 
migrated towards the bottom well when compared to 
Unconditioned Medium (p < 0.001; Newman-Keuls Multiple 
Comparisons Test).Cancer Cell International 2006, 6:1 http://www.cancerci.com/content/6/1/1
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Glioma cell lines express SCF and mouse ES cells express c-
kit
Given that SCF elicited migration of neural progenitors
derived from ES cells, we tested whether the three glioma
cell lines expressed SCF. Splice variants of human SCF give
rise to two forms of SCF, secreted and membrane bound.
SCF transcripts containing exon 6 give rise to protein with
an extracellular cleavage site that leads to production of
soluble SCF [18]. We designed PCR primers that would
result in a 665 bp product if the exon 6 coding region is
present. Using RT-PCR we observed expression of a 665
bp mRNA in all three glioma cell lines (Fig. 3A), indicat-
ing synthesis of the secreted form of SCF.
Using RT-PCR and primers specific for mouse c-kit (318
bp PCR product), we confirmed that undifferentiated ES
cells and Day 4 and Day 8 induced cells expressed c-kit
(Fig. 3B). Expression of gylceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a house-keeping
control.
Discussion
Our results show that neural progenitors derived from
mouse ES cells migrate toward factor(s) secreted by gli-
oma cell lines U87, N1321 and C6. We show that these
glioma lines can synthesize SCF and that recombinant
SCF elicits migration by neuralized ES cells in an apparent
dose-dependent manner. This selective migration is con-
sistent with the expression of c-kit, the receptor for SCF, by
the ES cell-derived neural progenitors.
Prior to this study, little was known about the migratory
properties of undifferentiated ES cells [21-23]. In contrast
to neuralized ES cells, we found that in vitro undifferenti-
ated ES cells are highly migratory in all conditions. The
highly migratory nature of undifferentiated ES cells may
contribute to their unique roles in early embryonic devel-
opment, such as migration events leading to gastrulation.
The migration of neuralized ES cells towards conditioned
medium in vitro may not be selective for SCF because the
glioma cell lines likely produce other attractant factors.
However, the production of SCF by glioma cells and
expression of c-kit by neural precursors suggests that SCF
could mediate selective migration towards gliomas in vivo.
Our initial migration studies led to the question: what fac-
tors are secreted by the gliomas that act on neuralized ES
cells to elicit selective migration? Malignant gliomas
secrete a wide variety of factors, associated with their pro-
liferative and invasive programs, including cytokines,
interleukins and growth factors, such as TGF-β1 [24-26],
and matrix metalloproteinases [27]. The cytokine SCF
elicits selective migration of brain-derived neural stem/
progenitor cells in vitro [28] and is up-regulated in
response to brain injury [15]. We confirmed expression of
SCF by the human glioma cell line, U87 [19]. In addition,
we found that the human glioma cell line, N1321, and the
rat glioma cell line, C6, both express SCF, and the version
of SCF expressed by these cell lines contains exon 6. Exon
6 is present in the splice variant of SCF from which soluble
SCF is produced [18]. It is also known that many types of
stem cells express the receptor for SCF, c-kit [20,29,30].
We confirmed expression of c-kit  by undifferentiated
mouse ES cells [31] and found that neuralized ES cells
also express c-kit. The latter result is consistent with
expression of c-kit by neural stem cells as well as with the
attractant and survival effects of SCF on neural stem cells
[20,28]. It is possible that expression of c-kit in Day 8
All three glioma cell lines express the secreted version of  SCF (A), and the undifferentiated and neurzalized ES cells  express c-kit, the tyrosine kinase receptor for SCF Figure 3
All three glioma cell lines express the secreted version of 
SCF (A), and the undifferentiated and neurzalized ES cells 
express c-kit, the tyrosine kinase receptor for SCF. The ES 
cells expressed c-kit at 0, 4 and 8 Days of the induction pro-
tocol (B). A, Primers specific for the splice variant of SCF 
that contains exon 6, known to produce secreted SCF, were 
used in RT-PCR experiments on glioma cell lines N1321, 
U87, and C6. The predicted 665 bp product is produced by 
all three cell lines. B, RT-PCR and primers specific for mouse 
c-kit demonstrated that undifferentiated ES cells and Day 4 
and Day 8 neuralized ES cells express c-kit (318 bp PCR 
product). Primers specific for mouse GAPDH (154 bp PCR 
product) were used as loading controls and are shown for 
the corresponding days of induction (taken from the same 
gel as for c-kit expression). As a negative control reverse 
transcriptase (RT) was left out of the reaction mixture (- 
RT). No RT controls in B were pooled samples taken from 
cells at 0, 4 and 8 Days of induction. In the right column of A 
and B is shown a low DNA mass ladder (Invitrogen, Cat. # 
10068-013).Cancer Cell International 2006, 6:1 http://www.cancerci.com/content/6/1/1
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embryoid bodies (Fig. 3B) is due to the presence of neural
progenitors [1,3]. While our data suggest that SCF may be
involved in eliciting selective migration by neuralized ES
cells, glioma cell lines likely produce other attractants. In
the future, it will be important to test the contribution of
SCF (if any) to selective migration documented here by
adding antibodies to SCF to the top well, to potentially
block the actions of SCF diffusing from the bottom well.
Neural stem cells demonstrate remarkable tropism to fac-
tors produced by gliomas in vivo [8,12,16,32]. Impor-
tantly, they can be genetically modified to express
therapeutic transgenes. These transgenes can encode onc-
olytic agents, apoptosis-inducing factors, interleukins, fac-
tors that inhibit angiogenesis and factors that sensitize
tumor cells to traditional treatments for gliomas, such as
chemotherapy and radiation [11,32,33]. Recent results
show that transplanted neural precursors can improve sur-
vival and reduce tumor volume in rodent models with
introduced glioblastomas [8,11,34]. In fact, transplanted
and endogenous neural precursors as well as bone mar-
row-derived mesenchymal cells [35,36], may enhance sur-
vival after induction of glioblastomas in rodent models
[37]. The 4-/4+ induction protocol used here produces a
heterogeneous mixture of neural cells within the EBs. It
will be important to test whether neural progenitors, or
more mature neural cells present in Day 8 EBs, contribute
to the cell population that is selectively attracted to SCF
and to medium conditioned by the glioma cell lines.
Conclusion
Because of their highly invasive nature, most gliomas are
not eradicated by traditional therapies, and consequently
are often fatal [38]. Clearly, therapies using stem cells as
vectors to deliver anti-tumor agents offer a promising
direction for new treatment strategies [13,17,34,39]. In
addition, neural stem/progenitor cells derived from ES
cells could help rebuild regions of the CNS damaged by
glioma or its treatment (surgery, radiation therapy and/or
chemotherapy).
Methods
ES Cell cultures and neural induction
The B5 mouse ES cell line [3,40] was used for all experi-
ments. The ES cells were grown in embryonic stem cell
growth medium (ESGM) (as described previously [3]) for
2 days on gelatin-coated flasks until 70% confluent. The
cells were then dissociated at 37°C for 5 minutes (0.25%
Trypsin with 1 mM EDTA), passed into 4 gelatin-coated
flasks and incubated for an additional 2 days (37°C, 5%
C02). Then dissociated ES cells were transferred to
uncoated petri plates and induced (i.e., neuralized) to
become neural precursors as free floating embryoid bod-
ies (EBs), using a retinoic acid induction protocol devel-
oped by Gottlieb and colleagues [1,3]. Prior to migration
assays, EBs were grown for 4 days (Day 4) in embryonic
stem cell induction medium (ESIM = ESGM without β-
mercaptoethanol and Leukemia Inhibitory Factor) or for
an additional 4 days (Day 8) in ESIM plus all-trans retin-
oic acid (500 nM).
As we reported previously [3], post-induction EBs
obtained using B5 ES cells contain a majority of cells that
express the neural precursor marker Nestin, but these EBs
have substantial numbers of cells that label for neuronal
markers, such as β-III Tubulin and Neurofilament-M.
Therefore, cells used for the migration assays represent a
heterogeneous population, consisting primarily of neural
progenitors and/or neural-like cells. After induction, EBs
were treated with 0.25% Trypsin with 1 mM EDTA, disso-
ciated mechanically to a single cell suspension and 25,000
cells were added to each well of the top chamber.
Tumor cell lines
Human glioma cell lines N1321 and U87 and rat glioma
cell line C6 were grown in DMEM and 10% fetal bovine
serum supplemented with 100 U/ml Penicillin, 100 µg/
ml Streptomycin [41] for 2 days in Tissue Culture BD Fal-
con Flasks (Fisher; Cat. # 13-680-65). The U87 and C6 cell
lines were dissociated at 37°C for 2.5 minutes using
0.25% Trypsin with 1 mM EDTA. The N1321 cell line was
also dissociated for 2 minutes but using 0.05% Trypsin
with 1 mM EDTA. Cells were then passaged and incubated
for an additional 2 days (37°C, 5% C02). All cells (ES and
glioma cells) were tested for viability using Trypan blue
stain and live cells were counted using a hemocytometer.
Migration assays and statistical analyses
Cell migration tests were performed using the Neuro
Probe Standard 48 Well Chemotaxis Chamber (Cat. #
AP48). The lower well was filled with either Uncondi-
tioned Medium, medium conditioned by one of the gli-
oma cell lines (i.e., Conditioned Medium) or glioma cells
at a density of 50,000 cells per 30 µl. Conditioned
Medium was obtained by collecting medium from glioma
cell cultures after 2 days of incubation. In migration assays
involving SCF, recombinant SCF was added in the bottom
well at selected concentrations. A porous polycarbonate
membrane (8 µm pores) was coated with entactin-colla-
gen IV-laminin (Upstate Biotechnologies, Cat. # 08–110)
and placed on top of the bottom chamber.
Wells of the top chamber were filled with a suspension of
stem/progenitor cells in DMEM at a density of 25,000
cells per 50 µl with cells at three different stages of differ-
entiation as follows: undifferentiated embryonic stem
cells (Day 0) or stem cells at Day 4 or Day 8 of the induc-
tion protocol. Table 1 lists the components found in the
top and bottom wells for experiments described here.
Negative controls for cellular migration through the mem-Cancer Cell International 2006, 6:1 http://www.cancerci.com/content/6/1/1
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brane included: 1- DMEM alone in the top well and gli-
oma cells in the bottom well, and 2- DMEM alone in the
top well and Unconditioned Medium (DMEM and FBS)
in the bottom well (Table 1). The entire chamber was
placed in an incubator (37°C, 5% C02) for 4 hours. The
chamber was separated and cells on the polycarbonate
membrane were fixed in methanol for 10 minutes and
washed in PBS (4X for 2 minutes each). The fixed mem-
brane was stained for 3 hours with Hoechst 33358 nuclear
stain at 50 µg/ml to identify cells that had migrated
through the membrane pores. After staining, the mem-
brane was washed with PBS (5X for 2 minutes each). The
membrane was then placed on a slide for subsequent epi-
fluorescence microscopy.
Images were captured digitally using a Leica stereoscope,
Model MZFLIII, equipped with a CCD camera. Images
were saved as TIFF files using MagnaFire (Ver. 2.1c) and
analyzed using NIH Image (Ver. 1.62). The total numbers
of cells that migrated through the pores of the membrane
were counted. All experimental conditions were replicated
a minimum of three times, and all experiments were per-
formed at least three times.
Statistical comparisons of cell counts were made using
One-Way ANOVA and post hoc Dunnet Test and/or New-
man-Keuls Multiple Comparisons Test. Significance is
given at p < 0.05 level, unless otherwise noted.
RT-PCR
Total RNA isolation was performed using GenElute
according to manufacturer's instructions (Sigma-Aldrich,
Cat# RTN 10). The 50 µl isolate was treated with 5 µl
DNase1 and 5 µl Reaction Buffer for 10 minutes at 37°C.
Then, 5 µl stop buffer was added and the mixture held at
70°C for 10 minutes. The cDNA was created with Marli-
gen Biosciences Inc. First-Strand cDNA Synthesis System
(Cat#11801-100) as directed by the manufacturer. PCR
was run using Eppendorf's HotMasterMix (2.5X) (Cat#
954140181), 200 uM primers and 7 µl of cDNA template.
Controls lacking Reverse Transcriptase were included. In
Figure 3B, no RT controls were pooled prior to PCR. The
SCF primers used were 5'-AAGGGATCTGCAGGAATCGT-
GTGA-3' (forward) and 5'-TGCCCTTGTAAGACTTGG
CTGTCT-3' (reverse). The parameters were 32 cycles at
94°C for 1 min, 55°C for 1 min, and 72°C for 1 min, with
final elongation at 72°C for 10 minutes. The mouse c-kit
primers used were 5'-CCATGTGGCTAAAGATGAAC-3'
(upstream) and 5'-CTGCTGGTGCTCGGGTTTG-3'
(downstream) [15]. The GAPDH primers used were 5'-
TGATGGGTGTGAACCACGAGAA -3' (upstream) and 5'-
AGTGATGGCATGGACTGTGGTCAT-3' (downstream).
The parameters for c-kit and GAPDH amplification were
as follows: 30 cycles at 94°C for 30 sec, 54°C for 45 sec,
69°C for 45 sec, with final elongation at 69°C for 10 min-
utes.
Abbreviations
SCF, Stem Cell Factor; NSCs, neural stem cells; ES, embry-
onic stem; SDF1α, stromal cell-derived factor 1α; TGF-β1,
transforming growth factor-beta one; PT- PCR, reverse
transcriptase-polymerase chain reaction; ESGM, embry-
onic stem cell growth medium; ESIM, embryonic stem cell
induction medium; EBs, embryoid bodies; GAPDH, Gyl-
ceraldehyde-3-phosphate dehydrogenase.
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Table 1: Contents of Top and Bottom Wells for Migration Experiments




Days 0, 4, 8 and 
Glioma Cells
Days 0, 4, 8 and 
Conditioned 
Medium
Day 8 and rSCF Days 0, 4, 8 and 
Negative Control 
1*




D M E M XXXXX
Stem Cells X X X
Bottom Well
D M E M XXXXX
F B S XXXXX






Unconditioned Medium = DMEM and FBS
Abbreviations: rSCF, recombinant Stem Cell Factor; DMEM, Dulbecco's modified eagle medium; FBS, fetal bovine serumCancer Cell International 2006, 6:1 http://www.cancerci.com/content/6/1/1
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